Dr. Douglas Dieterich: “Confab Reveals Prevention Gains”
Antiretroviral treatment as prevention, long-acting HIV drugs, HIV cure research, and new treatments for hepatitis C were among the highlights discussed last week in Boston at the 21st Conference on Retroviruses and Opportunistic Infections, the largest annual HIV/AIDS medical meeting in the U.S. Gilead Sciences’ sofosbuvir (Sovaldi) and Janssen’s simeprevir (Olysio), approved late last year, are now "flying off the shelves" at a rate of about 2,000 prescriptions per week, said Meeting Co-Chair Douglas Dieterich, MD, Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai. Learn more